Form 4: Crinetics Pharmaceuticals Executive Jeff E. Knight Acquires Shares and Stock Options
SEC Form 4 Filing
Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, reports acquisition of shares and stock options.
Summary
- Jeff E. Knight, the Chief Operating Officer of Crinetics Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On March 4, 2024, Knight acquired 23,000 shares of common stock and 87,000 stock options.
- The common stock was acquired at a price of $0.00, representing restricted stock units.
- These restricted stock units vest 25% annually, starting on March 15, 2025.
- The stock options have an exercise price of $43.51 and vest in 48 equal monthly installments from March 4, 2024.
- Following these transactions, Knight beneficially owns 59,222 shares of common stock and 87,000 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The document is a neutral regulatory filing. The sentiment is moderately positive as it reflects executive compensation and alignment with company performance.
Positives
- The acquisition of shares and options by a key executive could be interpreted as a sign of confidence in the company's future prospects.
Future Outlook
The document does not contain specific forward-looking statements about the company's overall performance, but it does outline the vesting schedule for the acquired stock and options.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the compensation structure for a key executive at Crinetics Pharmaceuticals.
Stakeholder Impact
- Shareholders may view the executive's increased stake in the company positively.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of transaction: acquisition of common stock and stock options. |
| 03/04/2024 | Vesting commencement date for stock options. |
| 03/15/2025 | First vesting date for restricted stock units (25%). |
| 03/03/2034 | Expiration date for stock options. |
| 03/06/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.